Xeljanz: Is this Treatment for Rheumatoid Arthritis Really Worth It?
Rheumatoid arthritis is an illness that can affect all parts of the body. However, it is mainly characterized by severe joint inflammation. This may later spread to the eyes, lungs and tissues. RA is systemic illness that attacks the immune system of the body which causes inflammation and severe pain. It is prevalent more in women than men between the ages of 40-60 years old. This does not mean that males should not take necessary precautions to keep this disease at bay. Even children have been known to be affected by rheumatoid arthritis.
Over 1.7 million Americans suffer from this condition. And over 30 million have succumbed to this illness worldwide, according to the Center of Disease Control and Prevention. There are treatments available for RA. However, studies show that patients do not fully recover from the treatment that is administered.
Xeljanz is a recent and effective treatment option for people suffering from RA who have a poor response rate to other forms of treatment. The product was endorsed in November 2012 by the FDA and is taken 2 times daily. The drug was certified for use after 7 clinical trials showed that patients recorded improved physical mobility after it was administered.
The side effects for this drug include headaches, respiratory problems, fever, dark urine and a host of infections. Tofacitinib is an active ingredient in Xeljanz which triggers stomach pain, swelling of the face, lips, tongues and throat. It is also responsible for body aches, chest pains, painful urination, shortness of breath, mucus coughs, skin discoloration and loss of appetite.
Xeljanz has no record for harming unborn babies. However, pregnant women who use this drug need to be monitored around the clock. They should desist from using the drug if they notice any unusual happenings in their bodies. Xeljanz can lead to plenty of opportunistic infections because there is a breakdown of the immune system including cancers, lymphoma and tubercolosis.
This drug also increases liver enzyme trials, cholesterol and reduces the volume of blood count. Xeljanz was certified alongside a Risk Evaluation and Mitigation Strategy (REMS). And what this means is that the drug comes with a medication guide espousing critical pointers and safety precautions for patients as well as information about the healthcare providers available in case the side effects spiral out of control or taken a turn for the worse.
Xeljanz is manufactured by Pfizer, a pharmaceutical company that has continually improved the health and overall well-being of humans by confronting and challenging all diseases known to man. This product from Pfizer is the most effective treatment available for RA. Despite the overwhelming side-effects that come with it.
Yes, smoking is linked to the development of rheumatoid arthritis, particularly for people who have smoked 20 years or longer.Smokers also have an increased risk of more-severe rheumatoid arthritis. In addition, they may be less likely to experience remission.
Smoking decreases the effectiveness of some drugs used to treat rheumatoid arthritis and can be a barrier to engaging in activities that may relieve symptoms of rheumatoid arthritis, such as exercise.
The exact reason why smoking is linked to rheumatoid arthritis isn’t well understood, but researchers suspect smoking somehow ignites faulty immune system functioning in people genetically predisposed to getting rheumatoid arthritis.
IQOS USA is a new, innovative way to enjoy real tobacco. Its HeatControl™ Technology heats the tobacco without burning it.
While the idea of heating tobacco (instead of burning it) has been around for more than two decades, it took years of research and development to create a product that is acceptable to adult consumers. Around 14 million consumers have already chosen to switch to this product: tobacco heating system IQOS (THS), and stopped smoking.
At the heart of THS are sophisticated electronics that heat specially designed heated tobacco units. THS heats the tobacco just enough to release a nicotine-containing tobacco vapor but without burning the tobacco.